Dr. Mian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 216-444-2200Fax+1 216-444-9423
Summary
- Dr. Omar Mian is a radiation oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from Virginia Commonwealth University School of Medicine and completed residency at Johns Hopkins Hospital. He specializes in urologic cancer.
Education & Training
- Johns Hopkins UniversityResidency, Radiation Oncology, 2012 - 2016
- Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2011 - 2012
- Virginia Commonwealth University School of MedicineClass of 2011
Certifications & Licensure
- OH State Medical License 2016 - 2026
- WA State Medical License 2024 - 2025
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- ACS Research Scholar Award American Cancer Society, 2020
- NCCN Young Investigator Award National Comprehensive Cancer Network, 2020
- SBUR Young Investigator Award Society of Basic Urologic Research, 2020
- Join now to see all
Publications & Presentations
PubMed
- 142 citationsNCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.Thomas W Flaig, Philippe E Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs
Journal of the National Comprehensive Cancer Network. 2022-08-01 - 8 citationsLineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.Jarrell Imamura, Shinjini Ganguly, Andrew Muskara, Ross S Liao, Jane K Nguyen
Frontiers in Endocrinology. 2023-01-01 - 65 citationsResistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressuresRobert Vander Velde, Nara Yoon, Viktoriya Marusyk, Arda Durmaz, Andrew Dhawan
Nature Communications. 2020-05-14
Journal Articles
- Use of 5-alpha-reductase inhibitors as alternatives to luteinizinghormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapyBae HJ, Mian Omar Y, Vaidya D, DeWeese TL, Song DY, Pract Radiat Oncol, 1/10/2017
- Current controversies in prostate brachytherapy for prostate cancerIbrahim Abu-Gheida, Christopher Fleming, Paul Ramia, Omar Mian, Rahul Tendulkar and Jay Ciezki, MD, Applied Radiation Oncology, 1/1/2017
- The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of originMian OY, Tendulkar RD, Abazeed ME., Transl Cancer Res, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Genetic and Epigenetic Profiling of Small Cell Bladder Cancer (SCBC).Petros Grivas, Vadim S. Koshkin, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse McKenney, Karen Streator Smith, Bonnie Shadrach, Kumiko Isse, Laura R. Saun..., ASTRO Annual Meeting, 1/1/2017
- Molecular Profiling of Small Cell Bladder Cancer (SCBC) Reveals Gene Expression Determinants of an Aggressive PhenotypeVadim S. Koshkin, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse McKenney, Karen Streator Smith, Bonnie Shadrach, Kumiko Isse, Laura R. Saunders, Ming Hu, ..., ASCO Annual Meeting, 1/1/2017
- DNA Methylation and H3K27M Mutant Allele Frequency as a biomarker of therapeutic response in DIPGAdam DeLong, Peter Anderson, Stephen Dombrowski, Erin Murphy, and Omar Mian, Lepow Day Research Presentation, CWRU SOM, 1/1/2017
- Join now to see all
Lectures
- Circulating tumor DNA (ctDNA) as a precision tool in radiotherapy.Washington, DC - 1/4/2017
- Controversies in the contemporary management of prostate cancer: Emerging role of biomarkersSheraton Hotel, Cordoba, Argentina - 1/2/2017
- Dosimetric Predictors of Sexual Function Decline Following LDR Brachytherapy for Prostate Cancer (PCa)San Antonio, TX - 1/1/2015
- Join now to see all
Other
- Integrated Molecular Profiling of GU Tumors: Applications for Personalized TherapyNature Webinar
Nature.com
1/28/2017 - Thesis, The Role of the Methyl DNA Binding Domain Protein 2 (MBD2) in Breast Cancer
Authored Content
- Transcriptomic and Protein Analysis of Small Cell Bladder Cancer Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target - Beyond the AbstractDecember 2018
- Persepctive - Stereotactic ablative radiotherapy for renal cell carcinoma safe in patients with solitary kidneyOctober 2018
Press Mentions
- Real-World Data Suggest Benefit From SBRT Plus Pembro in Advanced Bladder CancerOctober 1st, 2024
- Genetic and Pathologic Characteristics of Small Cell Bladder CancerNovember 13th, 2017
- Trimodality Therapy for Invasive Bladder CancerMarch 14th, 2017
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: